Advertiser / Brand
NAOS vs Revolution Beauty
Structured technology and market comparison · 2026
Direct Feature Comparison
NAOS · vs · Revolution BeautyFrench dermo-cosmetics group behind three skincare brands.
Public beauty brand selling makeup, skincare and haircare products.
Analyze all overlapping signals and tech stacks for NAOS and Revolution Beauty
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between NAOS and Revolution Beauty?
When comparing NAOS and Revolution Beauty, both platforms operate within the Advertiser / Brand ecosystem. NAOS is positioned as French dermo-cosmetics group behind three skincare brands, whereas Revolution Beauty focuses on Public beauty brand selling makeup, skincare and haircare products. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to NAOS and Revolution Beauty?
When evaluating NAOS and Revolution Beauty, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of NAOS and Revolution Beauty compare?
NAOS is headquartered in FR (founded in 1977) with 1,001–5,000 employees. Revolution Beauty is based in GB (founded in 2014) with 201–500 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: NAOS vs Revolution Beauty
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
NAOS
Recent Signals
No recent market signals documented for NAOS in the current tracking window.
Revolution Beauty
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Revolution Beauty (2026-08-19)
On August 17, 2026, the Compensation Committee of Revelation Biosciences, Inc. approved material restricted stock grants to executive leadership under its Amended and Restated 2021 Equity Incentive Plan. Chief Executive Officer James Rolke received 208,076 restricted shares, and Chief Financial Officer Chester S. Zygmont, III was granted 208,073 restricted shares. The equity awards are structured to vest across four equal 25% tranches linked to either reaching market capitalization hurdles of $30 million, $60 million, $90 million, and $120 million for 20 consecutive trading days, or time-based vesting at the two-year and four-year marks. The package aligns executive compensation with aggressive market valuation targets while providing retention security.
- CEO James Rolke and CFO Chester S. Zygmont, III were granted 208,076 and 208,073 restricted shares, respectively, under the 2021 Equity Incentive Plan.
- Awards vest in four equal 25% tranches upon reaching market capitalization thresholds of $30M, $60M, $90M, and $120M sustained over 20 consecutive trading days, or alternatively at 2-year (first two tranches) and 4-year (final two tranches) time intervals.
- Grants include standard accelerated vesting protections upon a Change in Control or qualified involuntary termination events.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners NAOS and Revolution Beauty share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks